# Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

> **NCT03572478** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Chicago** · enrollment: 12 (actual)

## Conditions studied

- Prostate Cancer
- Endometrial Cancer

## Interventions

- **DRUG:** Rucaparib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03572478
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-14
- **Primary completion:** 2020-02-29
- **Final completion:** 2020-10-01
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** The study was terminated due to lack of efficacy.
- **Last updated:** 2021-03-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03572478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03572478, "Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT03572478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*